Drug intelligence / Profile preview

CD133+ bone marrow-derived stem cells

Development stage: Phase 2
Lead developer: Royan Institute
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intrathecal

Overview

This autologous cell therapy, developed by the Royan Institute, consists of CD133-positive enriched bone marrow-derived progenitor cells for the treatment of cerebral palsy. The cells are harvested from the patient's posterior iliac crest and enriched using magnetic cell separation (CliniMACS) to a purity of 57-83%. Administered via intrathecal injection, these hematopoietic stem and progenitor cells are thought to exert therapeutic effects through paracrine signaling, anti-inflammatory actions, and immune modulation, rather than direct replacement of damaged neurons. Clinical evaluation has focused on children with spastic quadriplegic cerebral palsy to assess safety and functional improvement.

Other names: autologous CD133+ bone marrow-derived stem cellsCD133+ BMSC

Beyond the preview

Go deeper on CD133+ bone marrow-derived stem cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD133+ bone marrow-derived stem cells.

Explore the full profile